Publications by authors named "Giuseppe Salatiello"
Article Synopsis
- Studies show that platelet counts and PD-L1 expression are significantly higher in Stage IV NSCLC patients compared to earlier stages and healthy individuals.
- High levels of PD-L1 are linked to gene activity associated with tumor immune suppression, which impacts patient survival rates; longer survival is seen with high PD-L1 but not after disease progression.
- Research indicates that blocking PD-L1 with Atezolizumab may improve survival for Stage IV patients by reducing immune suppression, suggesting that PD-L1 levels could be useful for predicting responses to immunotherapy.
Immune checkpoint inhibitors against programmed cell death protein 1/programmed death-ligand 1 (PD-L1) have proven to be remarkably effective in non-small cell lung cancer. PD-L1 represents a predictive biomarker in lung cancer, although its heterogenous expression represents an emerging challenge for accurate biomarker-based patient selection. Lung adenocarcinomas (ADCs) show a high rate of intratumor morphologic heterogeneity that may reflect a heterogenous molecular and immunophenotypic profile.
View Article and Find Full Text PDF